Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Avec Les Echos suivez en temps réel toute l'actualité financière puisée aux meilleures sources des sociétés cotées.

Gilead Sciences’ seladelpar has won conditional marketing authorization to treat primary biliary cholangitis (PBC) alongside ...

Exelixis, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Klug, M.B.A., Appointed Chief Financial Officer and Chief Business Officer; Sophie Jeannin, M.D., Appointed Chief Medical ...

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments. Learn the critical warning signs of Primary biliary cholangitis (PBC) and ...